Compare Stocks

Date Range: 

 Novo Nordisk A/SMerck & Co., Inc.Abbott LaboratoriesAbbVieEli Lilly and
SymbolNYSE:NVONYSE:MRKNYSE:ABTNYSE:ABBVNYSE:LLY
Price Information
Current Price$92.60$76.87$120.98$116.30$243.50
50-Day Moving Average$84.54$76.71$115.12$115.16$225.56
52-Week Low$63.22$71.71$98.67$79.11$129.21
52-Week High$92.87$87.80$128.54$119.15$248.40
MarketRank™
Overall Score1.52.82.93.22.7
Analysis Score0.03.42.42.42.5
Community Score4.04.54.84.94.8
Dividend Score2.52.54.25.02.5
Ownership Score0.02.52.52.52.5
Earnings & Valuation Score1.31.30.61.31.3
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyBuy
Consensus Price TargetN/A$94.72$124.67$121.67$231.29
% Upside from Price TargetN/A23.23% upside3.05% upside4.62% upside-5.02% downside
Trade Information
Market Cap$218.05 billion$194.64 billion$214.96 billion$205.41 billion$233.52 billion
Beta0.420.410.680.830.26
Average Volume854,3457,822,7484,502,3515,294,6292,319,225
Sales & Book Value
Annual Revenue$19.45 billion$47.99 billion$34.61 billion$45.80 billion$24.54 billion
Price / Sales11.214.066.214.489.52
Cashflow$3.12 per share$7.39 per share$5.58 per share$13.73 per share$8.95 per share
Price / Cash29.7210.4021.708.4727.21
Book Value$4.12 per share$10.04 per share$18.62 per share$7.42 per share$6.09 per share
Price / Book22.487.666.5015.6739.98
Profitability
Net Income$6.46 billion$7.07 billion$4.50 billion$4.62 billion$6.19 billion
EPS$2.76$5.94$3.65$10.56$7.93
Trailing P/E Ratio32.1535.1034.0831.3536.40
Forward P/E Ratio27.5612.2425.968.3128.92
P/E Growth3.372.262.301.741.94
Net Margins33.77%11.48%15.85%10.28%23.91%
Return on Equity (ROE)71.90%53.80%27.00%136.75%132.28%
Return on Assets (ROA)30.84%16.15%12.39%12.95%16.36%
Dividend
Annual Payout$1.33$2.60$1.80$5.20$3.40
Dividend Yield1.44%3.38%1.49%4.47%1.40%
Three-Year Dividend Growth13.65%31.22%35.85%84.37%42.31%
Payout Ratio48.19%43.77%49.32%49.24%42.88%
Years of Consecutive Dividend Growth1 Years1 Years49 Years49 Years1 Years
Debt
Debt-to-Equity Ratio0.05%0.89%0.52%5.40%2.28%
Current Ratio0.85%1.02%1.75%0.83%1.42%
Quick Ratio0.59%0.78%1.32%0.73%1.10%
Ownership Information
Institutional Ownership Percentage5.56%71.71%72.99%65.98%81.57%
Insider Ownership Percentage0.07%0.32%1.50%0.09%0.13%
Miscellaneous
Employees45,32374,000109,00047,00035,000
Shares Outstanding2.35 billion2.53 billion1.78 billion1.77 billion959.03 million
Next Earnings Date8/5/2021 (Estimated)10/26/2021 (Estimated)10/20/2021 (Estimated)10/29/2021 (Estimated)8/3/2021 (Confirmed)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
Insulin Market Challenges Eli Lilly, Novo Nordisk, Biocon, etc.: Increased Business Risk after COVID-19Insulin Market Challenges Eli Lilly, Novo Nordisk, Biocon, etc.: Increased Business Risk after COVID-19
manometcurrent.com - July 31 at 6:09 PM
Lilly, Kumquat Biosciences collaborate to discover, develop & commercialize small molecules that stimulate tumor-specific immune responsesLilly, Kumquat Biosciences collaborate to discover, develop & commercialize small molecules that stimulate tumor-specific immune responses
pharmabiz.com - July 31 at 12:47 AM
Eli Lilly and Company [LLY] moved down -0.48: Why It’s ImportantEli Lilly and Company [LLY] moved down -0.48: Why It’s Important
dbtnews.com - July 30 at 7:46 PM
CDC Data on Delta’s Contagion Should Boost Covid Vaccines and DrugsCDC Data on Delta’s Contagion Should Boost Covid Vaccines and Drugs
barrons.com - July 30 at 2:46 PM
Eli Lilly (LLY) to Report Q2 Earnings: Whats in the Cards?Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?
finance.yahoo.com - July 30 at 2:46 PM
Whats in Store for Amgen (AMGN) This Earnings Season?What's in Store for Amgen (AMGN) This Earnings Season?
finance.yahoo.com - July 30 at 2:46 PM
Lilly, Kumquat Launch Up-to-$2B Immuno-Oncology CollaborationLilly, Kumquat Launch Up-to-$2B Immuno-Oncology Collaboration
genengnews.com - July 30 at 9:45 AM
Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology dealLilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
pmlive.com - July 30 at 9:45 AM
Eli Lilly’s New Compliance Chief on His PrioritiesEli Lilly’s New Compliance Chief on His Priorities
wsj.com - July 30 at 9:45 AM
FDA Late Wednesday Approved Eli Lilly And Incyte Arthritis Drug Baricitinib, In Combination With Remdesivir, To Treat COVID-19FDA Late Wednesday Approved Eli Lilly And Incyte Arthritis Drug Baricitinib, In Combination With Remdesivir, To Treat COVID-19
benzinga.com - July 29 at 6:33 PM
Regulators approve expanded emergency use of Eli Lillys COVID-19 treatmentRegulators approve expanded emergency use of Eli Lilly's COVID-19 treatment
wthr.com - July 29 at 6:33 PM
Lilly adds on to biomarker bombardment in Alzheimers with two new donanemab analysesLilly adds on to biomarker bombardment in Alzheimer's with two new donanemab analyses
fiercebiotech.com - July 29 at 6:33 PM
Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive declineLilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline
finance.yahoo.com - July 29 at 6:33 PM
U.S. FDA allows Eli Lilly’s COVID-19 drug to be taken without remdesivirU.S. FDA allows Eli Lilly’s COVID-19 drug to be taken without remdesivir
theglobeandmail.com - July 29 at 1:30 PM
Eli Lilly, Kumquat Biosciences Form Cancer Collaboration >LLYEli Lilly, Kumquat Biosciences Form Cancer Collaboration >LLY
marketwatch.com - July 29 at 1:30 PM
As COVID-19 case surge, Lilly reinstates mask restrictions on all workersAs COVID-19 case surge, Lilly reinstates mask restrictions on all workers
ibj.com - July 29 at 1:30 PM
FDA Broadens Authorization of Lillys COVID TreatmentFDA Broadens Authorization of Lilly's COVID Treatment
insideindianabusiness.com - July 29 at 1:30 PM
FDA broadens existing emergency use of Lilly and Incytes baricitinib in patients hospitalized with COVID-19 requiring oxygenFDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen
finance.yahoo.com - July 29 at 1:30 PM
U.S. FDA allows Lillys COVID-19 drug to be taken without remdesivirU.S. FDA allows Lilly's COVID-19 drug to be taken without remdesivir
finance.yahoo.com - July 29 at 1:30 PM
U.S. FDA allows Lilly’s COVID-19 drug to be taken without remdesivirU.S. FDA allows Lilly’s COVID-19 drug to be taken without remdesivir
financialpost.com - July 29 at 11:11 AM
Gastrointestinal Cancer Devices Market is Anticipated to Gain Moderate CAGR by 2027 Covid-19 Analysis | Eli Lilly, NovartisGastrointestinal Cancer Devices Market is Anticipated to Gain Moderate CAGR by 2027 Covid-19 Analysis | Eli Lilly, Novartis
openpr.com - July 29 at 8:06 AM
Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune ResponsesLilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses
finance.yahoo.com - July 29 at 8:06 AM
Lilly signs deal with Kumquat BiosciencesLilly signs deal with Kumquat Biosciences
finance.yahoo.com - July 29 at 8:06 AM
Eli Lilly and (NYSE:LLY) Receives New Coverage from Analysts at TruistEli Lilly and (NYSE:LLY) Receives New Coverage from Analysts at Truist
americanbankingnews.com - July 29 at 1:32 AM
Eli Lilly and (NYSE:LLY) Coverage Initiated by Analysts at TruistEli Lilly and (NYSE:LLY) Coverage Initiated by Analysts at Truist
marketbeat.com - July 29 at 12:15 AM
Eli Lilly and (NYSE:LLY) Reaches New 1-Year High at $246.19Eli Lilly and (NYSE:LLY) Reaches New 1-Year High at $246.19
americanbankingnews.com - July 28 at 11:13 AM
Eli Lilly and (NYSE:LLY) Receives "Buy" Rating from MizuhoEli Lilly and (NYSE:LLY) Receives "Buy" Rating from Mizuho
marketbeat.com - July 7 at 12:06 PM
3 Recession-Proof Dividend Stocks to Buy Now (LLY)3 Recession-Proof Dividend Stocks to Buy Now (LLY)
marketbeat.com - February 1 at 5:14 PM
DateCompanyBrokerageAction
7/30/2021Merck & Co., Inc.SVB Leerink
Boost Price Target
7/27/2021Merck & Co., Inc.Truist Securities
Initiated Coverage
7/27/2021Merck & Co., Inc.Truist
Initiated Coverage
7/27/2021AbbVieTruist Securities
Initiated Coverage
7/27/2021AbbVieTruist
Initiated Coverage
7/27/2021Eli Lilly andTruist
Initiated Coverage
7/23/2021Abbott LaboratoriesMorgan Stanley
Boost Price Target
7/23/2021Abbott LaboratoriesCredit Suisse Group
Boost Price Target
7/23/2021Abbott LaboratoriesRaymond James
Boost Price Target
7/20/2021Abbott LaboratoriesSVB Leerink
Boost Price Target
7/19/2021Novo Nordisk A/SBarclays
Reiterated Rating
7/15/2021Novo Nordisk A/SDeutsche Bank Aktiengesellschaft
Reiterated Rating
7/12/2021Abbott LaboratoriesWells Fargo & Company
Boost Price Target
7/7/2021Eli Lilly andMizuho
Reiterated Rating
7/6/2021Eli Lilly andBarclays
Boost Price Target
7/2/2021AbbVieDaiwa Capital Markets
Initiated Coverage
7/2/2021Eli Lilly andTruist Securities
Boost Price Target
7/2/2021Eli Lilly andTruist
Boost Price Target
6/24/2021Eli Lilly andCantor Fitzgerald
Boost Price Target
6/24/2021Eli Lilly andCowen
Boost Price Target
6/15/2021Eli Lilly andJPMorgan Chase & Co.
Boost Price Target
6/14/2021Eli Lilly andThe Goldman Sachs Group
Boost Price Target
6/9/2021Merck & Co., Inc.JPMorgan Chase & Co.
Lower Price Target
6/8/2021Eli Lilly andTruist Securities
Reiterated Rating
6/8/2021Eli Lilly andTruist Financial
Reiterated Rating
6/7/2021Merck & Co., Inc.Truist Securities
Lower Price Target
6/3/2021Merck & Co., Inc.SVB Leerink
Lower Price Target
6/2/2021Abbott LaboratoriesBTIG Research
Lower Price Target
6/2/2021Abbott LaboratoriesCredit Suisse Group
Lower Price Target
6/2/2021Abbott LaboratoriesBarclays
Lower Price Target
6/2/2021Abbott LaboratoriesWells Fargo & Company
Lower Price Target
6/2/2021Abbott LaboratoriesRaymond James
Lower Price Target
6/2/2021Abbott LaboratoriesMorgan Stanley
Lower Price Target
6/2/2021Abbott LaboratoriesCitigroup
Reiterated Rating
5/24/2021Abbott LaboratoriesBarclays
Initiated Coverage
5/20/2021Merck & Co., Inc.Argus
Reiterated Rating
5/3/2021AbbVieBMO Capital Markets
Boost Price Target
5/3/2021AbbVieMizuho
Boost Price Target
4/30/2021Merck & Co., Inc.SVB Leerink
Lower Price Target
4/30/2021AbbViePiper Sandler
Boost Price Target
4/28/2021Eli Lilly andMorgan Stanley
Lower Price Target
4/28/2021Eli Lilly andMizuho
Lower Price Target
4/28/2021Eli Lilly andBarclays
Lower Price Target
4/21/2021Abbott LaboratoriesMorgan Stanley
Boost Price Target
4/20/2021Abbott LaboratoriesWilliam Blair
Reiterated Rating
4/15/2021Abbott LaboratoriesAtlantic Securities
Initiated Coverage
4/7/2021AbbVieRoyal Bank of Canada
Initiated Coverage
3/30/2021AbbVieSVB Leerink
Boost Price Target
3/15/2021Eli Lilly andTruist Securities
Boost Price Target
3/11/2021Abbott LaboratoriesRaymond James
Boost Price Target
2/12/2021Eli Lilly andCowen
Boost Price Target
2/11/2021Novo Nordisk A/SUBS Group
Reiterated Rating
2/5/2021Merck & Co., Inc.Cantor Fitzgerald
Reiterated Rating
2/4/2021Novo Nordisk A/SBarclays
Reiterated Rating
2/4/2021AbbVieSVB Leerink
Boost Price Target
2/4/2021AbbVieRoyal Bank of Canada
Boost Price Target
2/4/2021AbbVieMizuho
Boost Price Target
2/4/2021Eli Lilly andMorgan Stanley
Boost Price Target
2/1/2021Eli Lilly andTruist
Boost Price Target
2/1/2021Eli Lilly andMizuho
Boost Price Target
2/1/2021Eli Lilly andBarclays
Boost Price Target
1/28/2021Abbott LaboratoriesWells Fargo & Company
Boost Price Target
1/28/2021Abbott LaboratoriesCowen
Boost Price Target
1/28/2021Abbott LaboratoriesCredit Suisse Group
Boost Price Target
1/28/2021Abbott LaboratoriesMorgan Stanley
Boost Price Target
1/28/2021Abbott LaboratoriesSVB Leerink
Boost Price Target
1/28/2021Abbott LaboratoriesRaymond James
Boost Price Target
1/28/2021Abbott LaboratoriesBTIG Research
Upgrade
1/28/2021AbbVieMorgan Stanley
Lower Price Target
1/22/2021Eli Lilly andBank of America
Boost Price Target
1/20/2021Novo Nordisk A/SCredit Suisse Group
Downgrade
1/19/2021Eli Lilly andMizuho
Upgrade
1/15/2021Novo Nordisk A/SDeutsche Bank Aktiengesellschaft
Initiated Coverage
1/12/2021Eli Lilly andTruist
Boost Price Target
12/16/2020AbbVieSVB Leerink
Boost Price Target
12/16/2020Eli Lilly andMizuho
Boost Price Target
12/15/2020Abbott LaboratoriesMorgan Stanley
Boost Price Target
12/15/2020AbbVieMizuho
Boost Price Target
12/10/2020Eli Lilly andWolfe Research
Upgrade
12/6/2020Merck & Co., Inc.Mizuho
Reiterated Rating
11/30/2020AbbVieMorgan Stanley
Boost Price Target
11/18/2020AbbVieBMO Capital Markets
Initiated Coverage
11/12/2020Novo Nordisk A/SJPMorgan Chase & Co.
Reiterated Rating
11/10/2020Merck & Co., Inc.Sanford C. Bernstein
Reiterated Rating
11/10/2020AbbVieSanford C. Bernstein
Initiated Coverage
11/6/2020Novo Nordisk A/SMorgan Stanley
Downgrade
11/3/2020Novo Nordisk A/SSociete Generale
Reiterated Rating
11/2/2020AbbVieSVB Leerink
Lower Price Target
10/29/2020Merck & Co., Inc.SVB Leerink
Boost Price Target
10/23/2020Merck & Co., Inc.Truist
Initiated Coverage
10/23/2020AbbVieTruist
Initiated Coverage
10/20/2020AbbVieThe Goldman Sachs Group
Downgrade
10/16/2020Merck & Co., Inc.JPMorgan Chase & Co.
Boost Price Target
10/16/2020AbbVieJPMorgan Chase & Co.
Boost Price Target
10/15/2020Novo Nordisk A/SMorgan Stanley
Reiterated Rating
9/29/2020Novo Nordisk A/SBerenberg Bank
Initiated Coverage
9/29/2020Merck & Co., Inc.Berenberg Bank
Initiated Coverage
9/29/2020AbbVieBerenberg Bank
Initiated Coverage
9/27/2020AbbVieMizuho
Reiterated Rating
9/22/2020Merck & Co., Inc.Mizuho
Reiterated Rating
9/2/2020AbbVieCitigroup
Boost Price Target
8/25/2020Merck & Co., Inc.SVB Leerink
Boost Price Target
8/20/2020AbbVieMorgan Stanley
Boost Price Target
8/18/2020Novo Nordisk A/SUBS Group
Reiterated Rating
8/4/2020Merck & Co., Inc.Royal Bank of Canada
Reiterated Rating
8/3/2020Novo Nordisk A/SMorgan Stanley
Reiterated Rating
8/3/2020Merck & Co., Inc.The Goldman Sachs Group
Upgrade
7/31/2020Merck & Co., Inc.Mizuho
Reiterated Rating
7/6/2020Novo Nordisk A/SBank of America
Downgrade
6/23/2020Merck & Co., Inc.Mizuho
Reiterated Rating
6/23/2020Merck & Co., Inc.Morgan Stanley
Reiterated Rating
6/12/2020Merck & Co., Inc.Wolfe Research
Downgrade
5/18/2020Novo Nordisk A/SMorgan Stanley
Reiterated Rating
5/13/2020Novo Nordisk A/SJPMorgan Chase & Co.
Reiterated Rating
5/11/2020Novo Nordisk A/SUBS Group
Downgrade
5/7/2020Novo Nordisk A/SSociete Generale
Reiterated Rating
5/4/2020Novo Nordisk A/SCowen
Initiated Coverage
5/4/2020Merck & Co., Inc.Credit Suisse Group
Reiterated Rating
4/29/2020Merck & Co., Inc.Guggenheim
Lower Price Target
3/23/2020Novo Nordisk A/SUBS Group
Upgrade
3/16/2020Novo Nordisk A/SBank of America
Upgrade
1/3/2020Novo Nordisk A/SGuggenheim
Downgrade
11/27/2019Novo Nordisk A/SBarclays
Upgrade
11/22/2019Novo Nordisk A/SPareto Securities
Downgrade
11/18/2019Novo Nordisk A/SUBS Group
Downgrade
(Data available from 8/1/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.